Skip to Main Content

Paper Details

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
J Manag Care Spec Pharm
0
2021
Author NameAffiliation
David L VeenstraUniversity of Washington Department of Pharmacy
  • 1 - 1

Datasets

Release 1.2